GLP-1 Shortage Status: What the FDA Actually Declared and When

"There's a GLP-1 shortage" was true for years and is now a stale headline more often than not. The FDA doesn't leave shortage status to interpretation — it issues formal declaratory orders with specific dates, and those orders are what actually changed the rules for every compounding pharmacy in the country. Here's what the FDA declared, when, and why it still matters even though the shortage itself is behind us.

The two declaratory orders

On December 19, 2024, the FDA issued a declaratory order removing tirzepatide injection products (Mounjaro and Zepbound) from its drug shortage list, based on an analysis that the shortage had been resolved¹. On February 21, 2025, the FDA issued a second declaratory order doing the same for semaglutide injection products (Ozempic and Wegovy)¹. The decisions changed the shortage-based conditions for compounding copies. FDA then described limited periods of enforcement discretion to allow a transition; the shortage-resolution dates and the end of those periods were not the same dates.

What changed for compounders

A shortage can provide a basis for compounding copies that would otherwise be restricted. After these shortages ended, FDA offered temporary enforcement discretion for certain violations tied to shortage-list status. That policy did not excuse unsafe products or violations of other requirements¹.

Source: FDA's policy updates of February 11, March 10 and April 28, 2025¹. The district court denied the tirzepatide preliminary-injunction motion on March 5 and the semaglutide motion on April 24. FDA's subsequent updates confirmed the applicable transition dates.

These were the ends of shortage-related enforcement discretion, not a statement that every patient-specific compounded prescription became illegal. Other compounding conditions remain relevant. Under 503A, a prescriber may determine and document a change that produces a significant difference for an identified individual patient, subject to all other applicable requirements. Under 503B, bulk-ingredient restrictions are a separate issue: FDA's April 2026 clarification says semaglutide and tirzepatide are on neither the 503B bulks list nor the shortage list¹.

The October 2026 update

FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list on April 30, 2026. The extended comment deadline was July 30. Those sources describe a proposal and public-comment process, not a final nationwide ban³⁴.

In its September 18 warning letter to Empower Pharmacy, FDA questioned vitamin-added formulations and missing or repeated patient-specific determinations. This was a letter about a particular facility, rather than a finding about every compounded prescription⁵. See is compounded semaglutide or tirzepatide still legal? for the current prescribing distinctions and what to ask before paying.

Why this still matters in 2026

If you're evaluating a program that offers "compounded semaglutide" or "compounded tirzepatide" today, the shortage-based legal justification for that practice is gone as of the dates above. That doesn't mean every compounded offer you see is automatically illegitimate — some compounding continues under other lawful bases, like personalized formulations for a specific patient need that FDA-approved products don't meet — but it does mean "there's a shortage, so this is legal" is no longer an accurate explanation for a compounded GLP-1 offer. A program that's transparent about why it's still compounding, and names a licensed, verifiable pharmacy, is giving you something to check. One that leans on outdated shortage language is worth extra scrutiny — see the full vetting checklist in how to verify a compounding pharmacy is legitimate.

Check the live status yourself

Shortage determinations are dynamic, and the FDA maintains a searchable drug shortage database as the authoritative, current source — it's the tool to check directly rather than relying on any article, including this one, for a real-time answer². If you're weighing a compounded option because you assume brand-name supply is still constrained, verify that assumption first.

"Resolved" describes a legal status, not a promise

One more distinction worth holding onto: an FDA declaratory order resolving a shortage is a determination based on the manufacturer's ability to meet current and projected demand at the time the order issued. It isn't a permanent guarantee against future supply disruption — the FDA can and does redeclare shortages if conditions change. If you're relying on brand-name availability, it's still worth checking the live database rather than assuming a 2024 or 2025 resolution is a fixed, unchangeable fact going forward².

Don't take "essential copies" as blanket cover

Since it's the exception that keeps getting cited, it's worth being skeptical of how it gets used. The guidance is narrow by design — it exists for documented, patient-specific reasons an FDA-approved product can't be used as-is, not as a general license to keep selling a cheaper copy of a drug that's back in full supply. If a program invokes this guidance to justify a compounded offer, ask what the specific, individual clinical reason is for your prescription rather than accepting the guidance's existence as blanket cover for the whole product line.

What this means for your provider decision

With the shortages resolved, compare approved-drug access and coverage first. A compounded option needs a patient-specific clinical assessment and an applicable legal basis; price and preference alone do not establish that it qualifies. Compounded products are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness or quality⁶. Compare the current cash-pay landscape on our semaglutide and tirzepatide price rankings, and weigh the cost trade-off directly in compounded vs brand-name GLP-1: which actually saves you money.

With the shortage-based justification gone for semaglutide and tirzepatide specifically, it's also worth knowing this doesn't apply to drugs that were never in shortage because they were never approved in the first place — see retatrutide: is it available yet, and is it safe to buy right now? for a current example of that different, higher-risk category.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.